Want to join the conversation?
In 3Q16, $ISRG's US procedures grew approx. 11% and outside of the US, procedures grew approx. 25%. In the United States, combined growth in mature procedures slowed in 3Q16. General and thoracic procedure growth remained healthy. In US gynaecology, procedures in 3Q16 grew modestly YoverY.
$TXMD flying high.. anyone here to catch..?
$CMG crashing. There seems to be nothing good to read about this company.